Prime Medicine, Inc.
PRME
$1.60
-$0.06-3.61%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 35.60% | -3.57% | -30.53% | -16.15% | -67.10% |
Total Depreciation and Amortization | 37.69% | 26.05% | 37.57% | 25.00% | 43.33% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 30.61% | 0.82% | 116.30% | 26.85% | -6.85% |
Change in Net Operating Assets | 238.13% | 611.80% | 14.98% | -249.48% | 1,133.99% |
Cash from Operations | 137.03% | 33.84% | -11.44% | -62.91% | -42.82% |
Capital Expenditure | 2.66% | 56.10% | 3.74% | -16.26% | 61.78% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 16.04% | 248.07% | -70.52% | -225.41% | 586.03% |
Cash from Investing | 16.88% | 233.29% | -75.26% | -192.40% | 401.64% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.48% | 12,011.01% | -- | 222,439.71% | -99.90% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -99.48% | 12,011.01% | -53.33% | 231,263.24% | -99.89% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 2,804.36% | 182.15% | -199.28% | 197.10% | -101.71% |